The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection
Authors:
Open Access
- 1 February 2016
- journal article
- research article
- Published by Springer Nature in Pilot and Feasibility Studies
- Vol. 2 (1) , 1-10
Abstract
Stage I non-small cell lung cancer (NSCLC) is potentially curable, and surgery is considered to be the standard of care for patients with good performance status and minimal co-morbidity. However, a significant proportion of patients with stage I NSCLC have a poorer performance status and significant medical co-morbidity that make them at higher risk of morbidity and mortality from surgery. Stereotactic ablative radiotherapy (SABR), which uses modern radiotherapeutic techniques to deliver large doses of radiation, has shown superiority over conventional radiotherapy in terms of local control and toxicity and is a standard of care for patients with stage I NSCLC who are at too high risk for surgery. However, it is not known whether surgery or SABR is the most effective in patients with stage I NSCLC who are suitable for surgery but are less fit and at higher risk surgical complications. Previous randomised studies have failed to recruit in this setting, and therefore, a feasibility study is required to see whether a full randomised control trial would be possible. SABRTooth is a UK-based, multi-centre, open-label, two-group individually (1:1) randomised controlled feasibility study in patients with peripheral stage I NSCLC considered to be at higher risk from surgical resection. The study will assess the feasibility of conducting a definitive large-scale phase III trial. The primary objective is to assess recruitment rates to provide evidence that, when scaled up, recruitment to a large phase III trial would be possible; the target recruitment being 54 patients in total, over a 21-month period. There are multiple secondary and exploratory objectives designed to explore the optimum recruitment and data collection strategies to help optimise the design of a future phase III trial. To know whether SABR is a better, equivalent or inferior alternative to surgery for higher risk patients is a key question in lung cancer. Other studies comparing SABR to surgery have closed early due to poor recruitment, and therefore, the SABRTooth feasibility study has been designed around the UK National Health Service (NHS) cancer pathway incorporating many design features in order to maximise recruitment for a future definitive phase III trial. controlled-trials.com ISRCTN13029788Keywords
Funding Information
- National Institute for Health Research (PB-PG-0613-31114)
This publication has 16 references indexed in Scilit:
- Comparison of 30-day, 90-day and in-hospital postoperative mortality for eight different cancer typesBritish Journal of Surgery, 2012
- Improving the recruitment activity of clinicians in randomised controlled trials: a systematic reviewBMJ Open, 2012
- Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 studyThe Lancet Oncology, 2007
- Outcomes of Sublobar Resection Versus Lobectomy for Stage I Non–Small Cell Lung Cancer: A 13-Year AnalysisThe Annals of Thoracic Surgery, 2006
- Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 CasesThe Annals of Thoracic Surgery, 2006
- Similar Long-term Survival of Elderly Patients With Non-small Cell Lung Cancer Treated With Lobectomy or Wedge Resection Within the Surveillance, Epidemiology, and End Results DatabaseChest, 2005
- Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: A single-institution studyThe Journal of Thoracic and Cardiovascular Surgery, 1997
- The Curative Treatment by Radiotherapy Alone of Stage I Non-Small Cell Carcinoma of the LungChest, 1995
- Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancerThe Annals of Thoracic Surgery, 1995
- Radiation therapy for medically inoperable stage I and II non-small cell lung cancerCancer Treatment Reviews, 1989